Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEBT-908 + Rituximab vs Standard of Care in Relapsed/Refractory DLBCL
NCT06792253Phase 3Recruiting
- Sponsor
- BeBetter Med
- Start
- Jan 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ifupinostat in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by BeBetter Med. Primary endpoint: Overall Survival up to 48 months. Started Jan 2025; status: recruiting.
02
Drugs
ifupinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06792253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792253.